Compositions and methods for treating cancer with anti-CD123 immunotherapy
AssigneeLentigen Technology, Inc.
InventorsDina Schneider, Zhongyu Zhu, Florian Tomszak, Rafijul Bari
Life of this patent
Estimating the term…
Abstract
Chimeric antigen receptors containing CD123 antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed.
Claims20
An isolated nucleic acid molecule encoding a chimeric antigen receptor (CAR) comprising amino acid residues 23 to 274 of the amino acid sequence of SEQ ID NO:
- 4.
A method of treating cancer in a subject in need thereof, the method comprising administering to the subject a pharmaceutical composition comprising an anti-tumor effective amount of a population of T cells, wherein the T cells comprise a nucleic acid sequence that encodes a chimeric antigen receptor (CAR), wherein the CAR comprises at least one extracellular antigen binding domain comprising a CD123 antigen binding domain comprising amino acid residues 23 to 274 of the amino acid sequence of SEQ ID NO:
- 4, at least one linker or spacer domain, at least one transmembrane domain, at least one intracellular signaling domain, wherein the T cells are T cells of the subject having cancer.
Dependencies are inferred from the claim text.